PMID- 29190831
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 11
DP  - 2017
TI  - Erectile dysfunction and quality of life in men receiving methadone or
      buprenorphine maintenance treatment. A cross-sectional multicentre study.
PG  - e0188994
LID - 10.1371/journal.pone.0188994 [doi]
AB  - BACKGROUND: Erectile dysfunction (ED) is common among men on opioid replacement
      therapy (ORT), but most previous studies exploring its prevalence and
      determinants yielded contrasting findings. Moreover, the impact of ED on
      patients' quality of life (QoL) has been seldom explored. OBJECTIVE: To explore
      the prevalence and determinants of ED in men on ORT, and the impact on QoL.
      METHODS: In a multicentre cross-sectional study, we recruited 797 consecutive
      male patients on methadone and buprenorphine treatment, collected data on
      demographic, clinical, and psychopathological factors, and explored their role as
      predictors of ED and QoL through univariate and multivariate analysis. ED
      severity was assessed with a self-assessment questionnaire. RESULTS: Nearly half 
      of patients in our sample were sexually inactive or reported some degree of ED.
      Some demographic, clinical and psychopathological variables significantly
      differed according to the presence or absence of ED. Multivariate regression
      analysis indicated that age, employment, smoke, psychoactive drugs, opioid
      maintenance dosage, and severity of psychopathological factors significantly
      influenced the risk and severity of ED. QoL was worse in patients with ED and
      significantly correlated with ED severity. Age, education, employment, opioid
      maintenance dosage, ED score, and severity of psychopathology significantly
      influenced QoL in the multivariate analysis. CONCLUSIONS: ED complaints can be
      explored in male opioid users on ORT through a simple and quick self-assessment
      tool. ED may have important effects on emotional and social well-being, and may
      affect outcome.
FAU - Lugoboni, Fabio
AU  - Lugoboni F
AD  - Department of Medicine, Addiction Medicine Unit, Verona University Hospital,
      Verona, Italy.
FAU - Zamboni, Lorenzo
AU  - Zamboni L
AD  - Department of Medicine, Addiction Medicine Unit, Verona University Hospital,
      Verona, Italy.
FAU - Federico, Angela
AU  - Federico A
AD  - Department of Medicine, Addiction Medicine Unit, Verona University Hospital,
      Verona, Italy.
AD  - Department of Neurosciences, Biomedicine and Movement Sciences, University of
      Verona, Verona, Italy.
FAU - Tamburin, Stefano
AU  - Tamburin S
AUID- ORCID: http://orcid.org/0000-0002-1561-2187
AD  - Department of Neurosciences, Biomedicine and Movement Sciences, University of
      Verona, Verona, Italy.
CN  - Gruppo InterSERT di Collaborazione Scientifica (GICS)
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20171130
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 40D3SCR4GZ (Buprenorphine)
RN  - UC6VBE7V1Z (Methadone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Buprenorphine/*administration & dosage
MH  - Cross-Sectional Studies
MH  - *Erectile Dysfunction
MH  - Humans
MH  - Male
MH  - Methadone/*administration & dosage
MH  - Middle Aged
MH  - Opiate Substitution Treatment/*adverse effects
MH  - Opioid-Related Disorders/*drug therapy/physiopathology
MH  - *Quality of Life
MH  - Young Adult
PMC - PMC5708835
EDAT- 2017/12/01 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/12/01 06:00
PHST- 2017/05/08 00:00 [received]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2017/12/01 06:00 [entrez]
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - 10.1371/journal.pone.0188994 [doi]
AID - PONE-D-17-17740 [pii]
PST - epublish
SO  - PLoS One. 2017 Nov 30;12(11):e0188994. doi: 10.1371/journal.pone.0188994.
      eCollection 2017.